

CITATION REPORT

List of articles citing

A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse

DOI: 10.1093/alcalc/35.6.587

Alcohol and Alcoholism, 2000, 35, 587-93.

Source: <https://exaly.com/paper-pdf/31967058/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
238	The new pharmacotherapies for alcohol dependence. 188-206		
237	Endogenous opiates: 2000. 2001 , 22, 2257-328		60
236	Gamma glutamyl transferase. 2001 , 38, 263-355		723
235	Naltrexone in the treatment of alcohol dependence. 2001 , 345, 1734-9		495
234	Opioid antagonists in the treatment of alcohol dependence. 2001 , 3, 484-8		7
233	Naltrexone and Cue Exposure With Coping and Communication Skills Training for Alcoholics: Treatment Process and 1-Year Outcomes. <i>Alcoholism: Clinical and Experimental Research</i> , 2001 , 25, 1634-1647	3.7	162
232	The Role of Biomarkers in Alcoholism Medication Trials. <i>Alcoholism: Clinical and Experimental Research</i> , 2001 , 25, 1119-1125	3.7	26
231	Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2001 , 25, 1335-1341	3.7	311
230	Naltrexone treatment for alcohol dependence. 2001 , 345, 1770-1		25
229	Pharmacological approaches to the treatment of excessive drinking and alcohol dependence. 2002 , 2, 119-25		2
228	Naltrexone for alcohol dependence. 2002 , 346, 1329-31; author reply 1329-31		10
227	Opioid antagonists for alcohol dependence. 2000 , CD001867		21
226	Advances in the Use of Naltrexone an Integration of Preclinical and Clinical Findings. 2002 , 217-245		13
225	Advances in the treatment of alcohol dependence. 2002 , 15, 255-260		
224	Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. 2002 , 22, 592-8		95
223	Clinical uses of naltrexone: A review of the evidence.. 2002 , 10, 213-227		42
222	Alcoholism Treatment Adherence: Older Age Predicts Better Adherence and Drinking Outcomes. <i>American Journal of Geriatric Psychiatry</i> , 2002 , 10, 740-747	6.5	90

221	Naltrexone improves outcome of a controlled drinking program. 2002 , 23, 361-6		25
220	New pharmacotherapies for alcohol dependence. 2002 , 177, 103-7		20
219	Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. 2002 , 176, 530-4		102
218	Using Acquired Knowledge and New Technologies in Alcoholism Treatment Trials. <i>Alcoholism: Clinical and Experimental Research</i> , 2002 , 26, 423-429	3.7	14
217	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2002 , 26, 1381-1387	3.7	86
216	Beta-phenylethylamines and the isoquinoline alkaloids. 2003 , 20, 342-65		41
215	Anti-dipsotropic isoflavones: the potential therapeutic agents for alcohol dependence. 2003 , 23, 669-96		32
214	Testing Combined Pharmacotherapies and Behavioral Interventions in Alcohol Dependence: Rationale and Methods. <i>Alcoholism: Clinical and Experimental Research</i> , 2003 , 27, 1107-1122	3.7	138
213	Current pharmacotherapies of alcoholism: a U.S. perspective. 2003 , 12, s53-s68		46
212	Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective. 2003 , 12, s69-s80		23
211	Barriers to the Use of Medications to Treat Alcoholism. 2003 , 12, 281-294		41
210	Patient Attitudes toward Treatment Predict Attendance in Clinical Pharmacotherapy Trials of Alcohol and Drug Treatment. 2003 , 12, 324-335		6
209	Research Advances in the Understanding and Treatment of Addiction. 2003 , 12, S36-S47		43
208	Measurement and prediction of medication compliance in problem drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2003 , 27, 1286-92	3.7	20
207	Treatment of alcohol abuse: an evidence-based review. <i>Alcoholism: Clinical and Experimental Research</i> , 2003 , 27, 1645-56	3.7	89
206	Diaryldimethylpiperazine ligands with mu- and delta-opioid receptor affinity: Synthesis of (+)-4-[(alphaR)-alpha-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide and (-)-4-[(alphaR)-alpha-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide.		3
205	Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. 2003 , 13, 469-75		56
204	Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. <i>Drug and Alcohol Dependence</i> , 2003 , 70, 85-91	4.9	99

203	Does acamprosate improve reduction of drinking as well as aiding abstinence?. 2003 , 17, 397-402		47
202	A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. 2003 , 28, 755-64		106
201	A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. 2003 , 28, 1546-52		525
200	Targeted naltrexone for early problem drinkers. 2003 , 23, 294-304		48
199	Special techniques. 2003 , 313-342		
198	Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. 2004 , 18, 293-335		127
197	Research Note [Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations. 2004 , 34, 451-480		34
196	Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. 2004 , 99, 811-28		387
195	Adherence to pharmacotherapy in patients with alcohol and opioid dependence. 2004 , 99, 1382-92		81
194	Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence. 2004 , 16, 233-8		12
193	A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2004 , 28, 736-45	3.7	38
192	Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2004 , 28, 1051-9	3.7	127
191	A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2004 , 28, 1356-61	3.7	69
190	Effectiveness of naltrexone in a community treatment program. <i>Alcoholism: Clinical and Experimental Research</i> , 2004 , 28, 1710-7	3.7	39
189	The dopamine D1 antagonist reduces ethanol reward for C57BL/6 mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2004 , 28, 1666-75	3.7	13
188	Naltrexone for alcohol-dependent patients. 2004 , 173, 34-7		13
187	Recent advances in the pharmacotherapy of alcoholism. 2004 , 6, 332-8		26
186	What place does naltrexone have in the treatment of alcoholism?. 2004 , 18, 547-60		24

185	An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. 2004 , 5, 1943-55		29
184	Pharmacotherapy of alcohol dependence: a review of the clinical data. 2004 , 18, 485-504		146
183	Opioids and alcoholism. 2004 , 81, 339-58		202
182	A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. 2004 , 24, 421-8		81
181	Controlled drinking: more than just a controversy. 2004 , 17, 175-187		38
180	Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers. 2004 , 72, 317-27		35
179	Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports. 2005 , 28, 87-9		11
178	Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. 2005 , 25, 349-57		81
177	A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. 2005 , 10, 289-92		20
176	Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies?. <i>Alcoholism: Clinical and Experimental Research</i> , 2005 , 29, 983-8	3.7	22
175	Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 2005 , 29, 1965-75	3.7	52
174	New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. 2005 , 526, 163-71		49
173	Recent advances in the treatment of alcoholism. 2005 , 5, 151-159		6
172	Naltrexone: clinical data. 2005 , 59-72		2
171	Development of medications for alcohol use disorders: recent advances and ongoing challenges. 2005 , 10, 323-43		30
170	How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. 2005 , 51, 59-66		96
169	Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?. <i>Alcohol and Alcoholism</i> , 2005 , 40, 227-33	3.5	73
168	Treatment of Late-Life Depression Complicated by Alcohol Dependence. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 491-500	6.5	47

167	The opioidergic-alcohol link : implications for treatment. 2005 , 19, 693-707		30
166	Opioid antagonists for alcohol dependence. 2005 , CD001867		117
165	Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. 2005 , 11, 83-91		82
164	A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. 2006 , 16, 311-23		60
163	An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. 2006 , 31, 1628-49		60
162	A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. <i>Drug and Alcohol Dependence</i> , 2006 , 85, 129-37	4.9	70
161	Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. 2006 , 47, 167-78		20
160	What works in alcohol use disorders?. 2006 , 12, 13-22		20
159	The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. 2006 , 26, 610-25		129
158	Attrition in a multi-component smoking cessation study for females. 2006 , 3, 59-71		18
157	Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. <i>Alcoholism: Clinical and Experimental Research</i> , 2006 , 30, 480-90	3.7	97
156	Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. 2006 , 101, 1451-62		122
155	New pharmacological approaches for the treatment of alcoholism. 2006 , 7, 2341-53		26
154	Long-acting injectable naltrexone for the treatment of alcohol dependence. 2007 , 7, 1265-77		90
153	Improving adherence in patients with alcohol dependence: a new role for pharmacists. 2007 , 64, S23-9		6
152	Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls. 2007 , 32, 439-49		81
151	Costs and outcomes of treatments for excessive alcohol consumption: Making policy decisions with the available data. 2007 , 14, 1-17		4
150	Emerging approaches to managing alcohol dependence. 2007 , 64, S12-22		25

149	Polymorphisms in the mu-opioid receptor gene (OPRM1) and the implications for alcohol dependence in humans. <i>Pharmacogenomics</i> , 2007 , 8, 1427-36	2.6	28
148	Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery. 2007 , 13, 201-6		14
147	Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. 2007 , 321, 544-52		69
146	The treatment of alcohol dependence. 2007 , 20, 222-7		29
145	The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. 2007 , 27, 112-5		18
144	Developing adaptive treatment strategies in substance abuse research. <i>Drug and Alcohol Dependence</i> , 2007 , 88 Suppl 2, S24-30	4.9	151
143	The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. 2007 , 17, 558-66		47
142	Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. 2007 , 17, 781-9		40
141	New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. 2007 , 61, 1290-5		39
140	Does naltrexone affect craving in abstinent opioid-dependent patients?. 2007 , 12, 176-82		19
139	Does matching matter? Examining matches and mismatches between patient attributes and therapy techniques in alcoholism treatment. 2007 , 102, 587-96		27
138	Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. <i>Alcoholism: Clinical and Experimental Research</i> , 2007 , 31, 1179-87	3.7	97
137	Naltrexone [®] suppressant effects on drinking are limited to the first 3 months of treatment. 2007 , 194, 1-10		8
136	Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. 2008 , 27, 115-22		29
135	Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial. 2008 , 17, 387-91		5
134	Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. 2008 , 17, 463-8		22
133	Topiramate for alcohol dependence. 2008 , 42, 1475-80		29
132	Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 2008 , 32, 498-504	3.7	31

131	A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. <i>Alcoholism: Clinical and Experimental Research</i> , 2008 , 32, 1299-308	3-7	44
130	Relationship between medication adherence and treatment outcomes: the COMBINE study. <i>Alcoholism: Clinical and Experimental Research</i> , 2008 , 32, 1661-9	3-7	32
129	Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. 2008 , 13, 124-9		32
128	[Referral to internal medicine for alcoholism: influence on follow-up care]. 2008 , 208, 499-505		1
127	A categorical typology of naltrexone-adopting private substance abuse treatment centers. 2008 , 34, 433-42		33
126	[Alcohol dependence: diagnosis and treatment]. 2008 , 29, 297-304		3
125	Beta-endorphin and drug-induced reward and reinforcement. 2008 , 86, 1-21		79
124	The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. 2008 , 34, 449-61		32
123	Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. 2008 , 22, 11-23		186
122	Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats. 2008 , 58, 81-90		7
121	A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. <i>Alcohol and Alcoholism</i> , 2008 , 43, 53-61	3-5	97
120	Issues in Designing and Conducting Clinical Trials for Reward Disorders: A Clinical View. 2008 , 41-57		
119	Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. 2008 , 33, 1856-63		82
118	Pharmacotherapy of alcohol misuse, dependence and withdrawal. 289-313		
117	Naltrexone in the treatment of alcohol dependence. 2008 , 2, 121-7		9
116	Reentry of the Addicted Certified Registered Nurse Anesthetist. 2009 , 20, 177-184		8
115	Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. 2009 , 287-310		3
114	A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. 2009 , 201, 611-8		70

113	Extended naltrexone and broad spectrum treatment or motivational enhancement therapy. 2009 , 206, 367-76		15
112	Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. 2009 , 28, 222-9		7
111	A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2009 , 33, 1863-97	3.7	76
110	Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. <i>Drug and Alcohol Dependence</i> , 2009 , 105, 256-8	4.9	26
109	Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia. 2009 , 35, 273-8		3
108	What is Relapse? A Contemporary Exploration of Treatment of Alcoholism. 2009 , 9, 245-262		4
107	Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol. 2009 , 33, 72-80		31
106	Management of alcohol use disorders. 2009 , 26, i-vii		1
105	Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation. <i>Alcoholism: Clinical and Experimental Research</i> , 2010 , 34, 317-30	3.7	23
104	Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. 2010 , 29, 568-75		15
103	The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. 2010 , 1, 26		17
102	Opioid antagonists for alcohol dependence. 2010 ,		80
101	Methodology of a randomized double-blind clinical trial for comorbid posttraumatic stress disorder and alcohol dependence. 2010 , 3, 131-147		19
100	An approach to the patient with substance use and abuse. 2010 , 94, 1169-205, x-i		20
99	Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities. 2010 , Suppl 6, 227-38		15
98	Opioid modulators for alcohol dependence. 2011 , 20, 1073-86		16
97	Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. 2011 , 17, 629-36		41
96	Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2011 , 35, 1804-11	3.7	15

95	Intramuscular extended-release naltrexone: current evidence. 2011 , 1216, 144-66	51
94	Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres. 2011 , 37, 673-84	17
93	Medical treatment of alcohol dependence: a systematic review. 2011 , 42, 227-66	72
92	Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. 2012 , 37, 445-55	60
91	Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. 2012 , 4, 116ra6	148
90	Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. 2012 , 20, 181-90	53
89	Do manualized psychosocial interventions help reduce relapse among alcohol-dependent adults treated with naltrexone or placebo? A meta-analysis. 2012 , 21, 501-7	9
88	A randomized trial evaluating an mHealth system to monitor and enhance adherence to pharmacotherapy for alcohol use disorders. 2012 , 7, 9	18
87	Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. 2012 , 103, 253-9	46
86	Treatments for Offenders in Prison and the Community. 2012 , 205-225	
85	Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. 2012 , 21, 55-62	60
84	Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. 2012 , 107, 709-18	137
83	The clinical significance of drug craving. 2012 , 1248, 1-17	294
82	Management of alcohol dependence in patients with liver disease. 2013 , 27, 287-99	66
81	Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. 2013 , 38, 2119-27	18
80	Opioid pharmacogenetics of alcohol addiction. 2013 , 3,	6
79	Pharmacotherapy for alcohol dependence: status of current treatments. 2013 , 23, 692-9	78
78	Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?. 2013 , 108, 275-93	241

77	Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. 2013 , 18, 937-46		77
76	Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. 2013 , 39, 144-60		17
75	The Opioid receptor and treatment response to naltrexone. <i>Alcohol and Alcoholism</i> , 2013 , 48, 402-8	3-5	30
74	Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time. 2013 , 33, 649-57		11
73	The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. <i>Alcoholism: Clinical and Experimental Research</i> , 2013 , 37, 2128-37	3-7	37
72	Variation in Mu-Opioid Receptor Gene as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort. 2013 , 1, 101		13
71	PTSD and comorbid AUD: a review of pharmacological and alternative treatment options. 2014 , 5, 25-36		31
70	Outcome predictors for problem drinkers treated with combined cognitive behavioral therapy and naltrexone. 2014 , 40, 103-10		6
69	Pharmacological approaches to reducing craving in patients with alcohol use disorders. 2014 , 28, 343-60		48
68	The role of the opioid system in alcohol dependence. 2014 , 28, 8-22		53
67	Pharmacologic treatment of alcoholism. 2014 , 125, 527-42		8
66	Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. 2014 , 231, 3843-53		40
65	The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. 2014 , 116, 107-15		6
64	Substance-Related Disorders: Alcohol-Related Disorders. 2015 , 1401-1434		2
63	The opioid receptors as targets for drug abuse medication. 2015 , 172, 3964-79		18
62	In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene. <i>PLoS ONE</i> , 2015 , 10, e0125953		16
61	Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. 2015 , 35, 13-22		7
60	Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers. 2015 , 29, 833-45		9

59	The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. 2015 , 110, 920-30		81
58	Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. 2015 , 230, 121-9		13
57	Kappa-opioid receptors differentially regulate low and high levels of ethanol intake in female mice. 2016 , 6, e00523		11
56	Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. 2016 , 39, 627-45		38
55	Mu-opioid receptor activation in the medial shell of nucleus accumbens promotes alcohol consumption, self-administration and cue-induced reinstatement. 2016 , 108, 14-23		19
54	Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?. 2016 , 30, 698-714		1
53	Naltrexone: A Pan-Addiction Treatment?. 2016 , 30, 719-33		40
52	Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. 2016 , 223, 253-67		9
51	Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. 2016 , 5, 141-9		9
50	Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers. 2016 , 3, 125-137		23
49	Alcohol addiction and the mu-opioid receptor. 2016 , 65, 228-33		11
48	Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. 2017 , 22, 581-615		41
47	A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking. <i>Alcoholism: Clinical and Experimental Research</i> , 2017 , 41, 644-652	3-7	6
46	Alcohol Stimulation and Sedation: a Critical Review of the Biphasic Alcohol Effects Scale. 2017 , 4, 209-220		1
45	The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial. 2017 , 77, 72-78		3
44	Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review. 2017 , 7, 211-224		11
43	Efficacy of Naltrexone for the Treatment of Alcohol Dependence in Latino Populations. 2017 , 78, 629-634		2
42	Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2018 , 42, 571-577	3-7	6

41	Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention. 2018 , 52, 787-797		11
40	Mobile alcohol biosensors and pharmacotherapy development research. 2019 , 81, 149-160		11
39	Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis. 2019 , 10, 1164		6
38	Psychological and endocannabinoid responses to aerobic exercise in substance use disorder patients. <i>Substance Abuse</i> , 2021 , 42, 272-283	3.8	8
37	Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis. <i>BMC Medicine</i> , 2019 , 17, 174	11.4	16
36	Opioid System and Alcohol Consumption. 2019 , 435-442		
35	Therapeutic Drug Monitoring of Naltrexone and 6-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. <i>Alcohol and Alcoholism</i> , 2019 , 54, 51-55	3.5	2
34	Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2020 , 25, 1749-1758	15.1	12
33	A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 1933-1951	3.7	8
32	Pharmacotherapies and personalized medicine for alcohol use disorder: a review. <i>Pharmacogenomics</i> , 2020 , 21, 1117-1138	2.6	3
31	Is craving a risk factor for substance use among treatment-seeking individuals with alcohol and other drugs use disorders? A meta-analytic review. <i>Drug and Alcohol Dependence</i> , 2020 , 212, 108002	4.9	9
30	Pharmacogenetics of addiction therapy. <i>Methods in Molecular Biology</i> , 2014 , 1175, 589-624	1.4	5
29	A Translational Approach to Novel Medication Development for Protracted Abstinence. <i>Current Topics in Behavioral Neurosciences</i> , 2012 , 647-670	3.4	7
28	Advances in the treatment of craving for alcohol and tobacco. 2007 , 211-237		6
27	Endogenous Opiates, Addiction, and the Stress Response. 2007 , 85-104		1
26	Treatment of late-life depression complicated by alcohol dependence. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 491-500	6.5	19
25	Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders. <i>PLoS ONE</i> , 2015 , 10, e0124613	3.7	24
24	Alcohol Use and Gamma-Glutamyltransferase Using a Mendelian Randomization Design in the Guangzhou Biobank Cohort Study. <i>PLoS ONE</i> , 2015 , 10, e0137790	3.7	9

23	Pharmacoprophylaxis of alcohol dependence: Review and update Part II: Efficacy. <i>Indian Journal of Psychiatry</i> , 2007 , 49, 26-33	2.2	6
22	Adding Psychotherapy to the Naltrexone Treatment of Alcohol Use Disorder: Meta-analytic Review. <i>Cureus</i> , 2018 , 10, e3107	1.2	2
21	Using Acquired Knowledge and New Technologies in Alcoholism Treatment Trials. <i>Alcoholism: Clinical and Experimental Research</i> , 2002 , 26, 423-429	3.7	
20	The Chemistry and Pharmacology of Delta Opioid Antagonists. 2009 , 119-136		
19	Addictive Disorders in Psychiatric Medicine. 197-218		
18	Encyclopedia of Clinical Neuropsychology. 2011 , 67-70		
17	Farmakoterapia wspomagajăca w leczeniu uzaleŹnienia od alkoholu i narkotykŹ. 2013 ,		
16	[Accuracy of the choice of the dependence syndrome treatment: evidence-based addictology against clinical practice]. <i>Zhurnal Nevrologii i Psikiatrii Imeni S S Korsakova</i> , 2015 , 115, 59-63	0.4	0
15	Alkoholbedingte Erkrankungen des Nervensystems. <i>Springer-Lehrbuch</i> , 2016 , 723-732	0.4	
14	Encyclopedia of Clinical Neuropsychology. 2017 , 1-5		
13	Encyclopedia of Clinical Neuropsychology. 2018 , 96-100		
12	Therapeutische Strategien bei Alkohol- und Tabakabhăngigkeit. 2020 , 189-270		
11	A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. <i>Indian Journal of Psychiatry</i> , 2020 , 62, 650-658	2.2	2
10	Therapeutic Strategies in Alcohol and Tobacco Addiction. 2020 , 195-270		
9	Characteristics Associated With High-Intensity Binge Drinking in Alcohol Use Disorder. <i>Frontiers in Psychology</i> , 2021 , 12, 750395	3.4	
8	Medikamente zur Behandlung von Abhăngigkeit und Entzugssymptomen. 2008 , 667-686		
7	Trust, performance management and the new GP contract. <i>British Journal of General Practice</i> , 2003 , 53, 754-5	1.6	3
6	Alcohol and primary care--will an emphasis upon harm reduction engage general practitioners?. <i>British Journal of General Practice</i> , 2003 , 53, 755-7	1.6	

5	The Lesch alcoholism typology - psychiatric and psychosocial treatment approaches. <i>Annals of Gastroenterology</i> , 2011 , 24, 89-97	2.2	7
4	Marketed New Drug Delivery Systems for Opioid Agonists/Antagonists Administration: A Rapid Overview. <i>Addiction and Health</i> , 2016 , 8, 115-122	0.9	
3	Pharmacological interventions for alcohol misuse in correctional settings: A systematic review. <i>Alcoholism: Clinical and Experimental Research</i> , 2021 ,	3.7	
2	Specialist treatment. 197-217		
1	Pharmacogenetics of Addiction Therapy. 2022 , 437-490		0